Gardiquimod
![]() | |
Identifiers | |
---|---|
| |
CAS Number | 1020412-43-4 |
PubChem (CID) | 44592366 |
ChemSpider | 24665048 |
ChEMBL | CHEMBL1085742 |
ECHA InfoCard | 100.233.311 |
Chemical and physical data | |
Formula | C17H23N5O |
Molar mass | 313.40 g·mol−1 |
3D model (Jmol) | Interactive image |
| |
| |
![]() ![]() |
Gardiquimod is a selective compound for mouse or human toll-like receptor 7 (TLR7) and acts as an immune response modifier.[1][2][3] The core structure is 1H-imidazo[4,5-c]quinoline like in both imiquimod and resiquimod. It is structurally extremely similar to resiquimod differing only by an oxygen for nitrogen switch.
References
- ↑ NCBI: “The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice”
- ↑ NCBI: Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells
- ↑ Nature.com: “Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells”
This article is issued from Wikipedia - version of the 10/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.